Literature DB >> 24603194

Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence.

M A Cañizares1, J M Matilla2, A Cueto3, J Algar4, I Muguruza5, N Moreno-Mata6, R Moreno-Balsalobre7, R Guijarro8, R Arrabal9, E Garcia-Fontan1, A Gonzalez-Piñeiro1, M Garcia-Yuste2.   

Abstract

BACKGROUND: Atypical carcinoids (AC) of the lung are rare intermediate-grade neuroendocrine neoplasms. Prognostic factors for these tumours are undefined.
METHODS: Our cooperative group retrieved data on 127 patients operated between 1980 and 2009 because of an AC. Several clinical and pathological features were studied.
RESULTS: In a univariable analysis, T-status (p=0.005), N-status (p=0.021), preoperative M-status (previously treated) (p=0.04), and distant recurrence developed during the outcome (p<0.001) presented statistically significant differences related to survival of these patients. In a multivariable analysis, only distant recurrence was demonstrated to be an independent risk factor for survival (p<0.001; HR: 13.1). During the monitoring, 25.2% of the patients presented some kind of recurrence. When we studied recurrence factors in a univariable manner, sublobar resections presented significant relationship with locoregional recurrence (p<0.001). In the case of distant recurrence, T and N status presented significant differences. Patients with preoperative M1 status presented higher frequencies of locoregional and distant recurrence (p=0.004 and p<0.001, respectively). In a multivariable analysis, sublobar resection was an independent prognostic factor to predict locoregional recurrence (p=0.002; HR: 18.1).
CONCLUSIONS: Complete standard surgical resection with radical lymphadenectomy is essential for AC. Sublobar resections are related to locoregional recurrence, so they should be avoided except for carefully selected patients. Nodal status is an important prognostic factor to predict survival and recurrence. Distant recurrence is related to poor outcome. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Year:  2014        PMID: 24603194     DOI: 10.1136/thoraxjnl-2013-204102

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  17 in total

Review 1.  Classification of lung neuroendocrine tumors: lights and shadows.

Authors:  Marco Volante; Gaia Gatti; Mauro Papotti
Journal:  Endocrine       Date:  2015-03-21       Impact factor: 3.633

Review 2.  Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.

Authors:  Edward M Wolin
Journal:  Oncologist       Date:  2015-08-25

3.  Ten-year Single Center Experience of Pulmonary Carcinoid Tumors and Diagnostic Yield of Bronchoscopic Biopsy.

Authors:  Renee K Dixon; Edward James Britt; Giora A Netzer; Majid Afshar; Allen Burke; Sandy Liu; Jeudy Jean; Nirav G Shah
Journal:  Lung       Date:  2016-08-20       Impact factor: 2.584

4.  Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought.

Authors:  Giacomo Cusumano; Ludovic Fournel; Salvatore Strano; Diane Damotte; Marie Christine Charpentier; Antonio Galia; Alberto Terminella; Maurizio Nicolosi; Jean Francois Regnard; Marco Alifano
Journal:  Lung       Date:  2017-10-11       Impact factor: 2.584

5.  A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Authors:  Marta Peri; Edoardo Botteri; Eleonora Pisa; Filippo De Marinis; Antonio Ungaro; Francesca Spada; Chiara Maria Grana; Roberto Gasparri; Lorenzo Spaggiari; Nicole Romentz; Giuseppe Badalamenti; Antonio Russo; Nicola Fazio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Prognostic significance of histopathological factors in survival and recurrence of atypical carcinoid tumours.

Authors:  Eva-María García-Fontán; Miguel-Ángel Cañizares-Carretero; Montserrat Blanco-Ramos; Jose-María Matilla-González; Rommel Carrasco-Rodríguez; Francisco Barreiro-Morandeira; Mariano García-Yuste
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

7.  Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors.

Authors:  Samira M Sadowski; Emanuel Christ; Benoit Bédat; Attila Kollár; Wolfram Karenovics; Aurel Perren; Frédéric Triponez
Journal:  Endocr Connect       Date:  2017-12-11       Impact factor: 3.335

8.  Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.

Authors:  Yunqiang Nie; Wei Gao; Na Li; Wenjun Chen; Hui Wang; Cuiyun Li; Haiyan Zhang; Ping Han; Yingmei Zhang; Xin Lv; Xinyi Xu; Hongyan Liu
Journal:  World J Surg Oncol       Date:  2017-03-03       Impact factor: 2.754

9.  Nodal involvement adversely affects prognosis in pulmonary carcinoid tumors.

Authors:  Demet Yaldız; Şeyda Örs Kaya; Kenan Can Ceylan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

10.  Outcomes after surgical resection of pulmonary carcinoid tumors.

Authors:  Ikenna C Okereke; Angela M Taber; Rogers C Griffith; Thomas T Ng
Journal:  J Cardiothorac Surg       Date:  2016-03-02       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.